Since its widespread clinical application in the late 1980 s transrectal ultrasound (TRUS) has improved to the stage where the gland can be examined with submillimeter precision. Anatomical accuracy, however, has not significantly improved diagnostic accuracy of prostate cancer. Early reports of prostate cancer maintained that cancers were hyperechoic on US, later followed by reports that most cancers were in fact hypoechoic and yet more modern data hold that the many cancers are isoechoic and indistinguishable from normal prostate tissue. This experience parallels the downward stage migration of prostate cancer at presentation. Visibility of a prostate cancer depends on extra tissue interfaces presented by tumour disorganisation or the surrounding tissue reaction induced by the cancer. Thus, advanced cancers are often hyperechoic, earlier cancers are distinguished by greater inflammatory or vascular reaction and are seen as hypoechoic areas whereas the earliest tumours are histologically bland with barely any surrounding reaction and thus are isoechoic, or effectively invisible, on current grey-scale ultrasound. With the increasing use of PSA testing, what may be called de facto screening, most prostate cancers present at an earlier, and therefore ultrasound invisible stage.
Thus, the central dilemma of modern prostate cancer diagnosis using TRUS is how to diagnose isoechoic cancers. Broadly, two separate strategies are being explored to improve the recognition of early, small volume tumours. The first is the use of more biopsies per gland and the second is to improve our ability to visualise subtle tissue abnormalities.
More biopsies per gland is the easier option and so far favoured. The first ultrasound-guided biopsies for prostate cancer diagnosis were reported in the early 1980 s. These were directed onto areas of hyperechoic or hypoechoic focal nodules, but most of these nodules proved to be histologically benign. The recognition that lesion-directed biopsies were often nondiagnostic led Hodge et al 1 to experiment with a sampling technique. In their landmark report they showed that cancer detection is improved if the gland is sampled in a systematic manner, an early recognition that many cancers are not seen on TRUS. A total of 52% of cancers in their study were isoechoic, identified by random systematic biopsies alone. This was a major advance in prostate cancer detection, but with wider experience even the sextant technique was found to be wanting, with a miss rate of 19-31% of tumours, and increasingly 8, 10, 12, 13 or even more cores are being advocated.
2-9 Figure 1 illustrates the many different biopsy trajectories studied and as yet there is no consensus about the ideal number of biopsies. Ideal being the minimum number of biopsies that will ensure recognition of all clinically significant tumours and at the time of writing between 8 and 12 biopsies per gland are being taken (Figure 2 ).
Improved diagnostic rate however has been tempered by concerns about an increased complication rate. Pain of TRUS biopsies has been controlled by the routine use of peri-prostatic local anaesthesia, more than halving the number of men who complain of moderate or severe pain. 10 Regarding other complications, pooled data from previous studies reveal a haematuria rate of 13-80%; haematospermia in 5-89% and between 2.4 and 37% notice per-rectal bleeding. In the vast majority, these bleeding complications are mild and self-limiting but rarely hospitalisation may be necessary because of major bleeding or septicaemia. Temporary urinary retention is also rare 11 but higher in those who have undergone 413 biopsies or if the urethra has been transgressed. Thus, there is concern that as we move to an era of more core biopsies per gland that the complication rates will also increase. 2 There are no comparative data as yet to allay these concerns and continued complication surveys and audits are important. Furthermore, taking more cores, although useful, is in its way a crude method. It is intrinsically inefficient. For example, in our experience a median of 2.1 cores out of 8-12 cores will be positive. Although a negative biopsy has some utility as it can contribute to local staging information, it may be argued that many prostate biopsies, and thus rectal mucosal and prostate gland punctures, are fruitless. Ideally, only one or a few cores should be necessary, all accurately targeted on the suspicious area with, say, a 450% positive rate. Even the most modern grey-scale TRUS machines are incapable of such targeted accuracy and novel ultrasound techniques are being explored.
The sonographic study of prostate cancer neovascularity has been explored. Histologically, it is known that prostate cancer like most other cancers requires neovascularity for invasion. 12, 13 Colour Doppler is an apparently easy method to visualise vascularity and has been widely explored, either as a stand-alone technique, or enhanced using ultrasound contrast media or threedimensional (3-D) anatomical visualisation. Intravascular microbubble contrast agents can improve the accuracy of prostate cancer detection, thereby reducing the number of biopsies required. Increased signal to noise ratio allows flow visualisation in vessels down to 40 mm in size using power Doppler, or more recently contrast specific harmonic imaging modes. An early study demonstrated 100% sensitivity for tumours of Gleason grade 7 and above with only low volume tumours, Gleason grade 6 being missed. 14 3-D imaging allows contrast evaluation in any plane, 15 that seems to improve detection of enhancement and morphological asymmetry, while dynamic enhancement curves may be able to distinguish between inflammatory change and neovascularisation and assess response to hormonal suppression. 16 All these promising data need to be explored further in routine clinical practice (Figure 3) .
Of more experimental techniques, ultrasound elastography is another promising area, 17 displaying tissue stiffness by calculating the relative displacement of speckle (artefact) echoes within the tissue upon manual compression. The resulting grey-scale image distinguishes hard tissue (malignant) from soft (normal) and may improve focal cancer detection. Finally, impedance endotomography may become an adjunct to TRUS imaging with the detection of areas of increased electrical impedance corresponding to likely malignancy. All these new ultrasound techniques are still at an early, exploratory stage and none, including colour Doppler-the most widely explored-can yet replace systematic prostate biopsy, but they illustrate the continuing attempts to improve the visualisation of prostate cancer.
To summarise, although ability to visualise and study the prostate gland has increased greatly, modern TRUS has not translated into substantially improved cancer detection without requiring biopsy confirmation. Instead of reduced biopsies the trend is towards taking more biopsies per gland. With the use of local anaesthetic this is well tolerated but it is not yet known whether more biopsies increase the complication rate. Concerns about increased complications, as well as the increasing number of negative biopsies necessary for each positive biopsy, means that new ultrasound techniques should, and are being explored to improve the visualisation of prostate cancer. TRUS and prostate biopsy U Patel
